Subsequently, the synergistic antitumor effect of co-treatment with RFA, si-PD-1, and si-TGF-β was confirmed in a xenograft model by measuring the tumor growth, survival rate, infiltration of CD8+ T cells, and activity of the PI3K/AKT/mTOR pathway. The gene discussed is CD8A; the disease is neoplasm.